# Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions

> **NCT01697020** · PHASE1 · COMPLETED · sponsor: **Nova Laboratories Limited** · enrollment: 70 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Mercaptopurine 20mg/ml oral suspension
- **DRUG:** Mercaptopurine 50mg tablet

## Key facts

- **NCT ID:** NCT01697020
- **Lead sponsor:** Nova Laboratories Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2013-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01697020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01697020, "Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01697020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*